Gender and immune response to meningitis B vaccine
Part of Brain & nervous system, Infections clinical trials.
This study tests how well the meningitis B vaccine works in transgender and cisgender people. It aims to understand if sex and gender affect immune responses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old
- You are in good general health and have a body mass index (BMI) between 18.5 and 35
- If you are transgender, you must have been on stable gender-affirming hormones for at least 6 months
- If you can become pregnant, you must not be pregnant or breastfeeding and must use birth control methods that are not hormonal (like a copper IUD or barrier methods)
- You cannot have had a meningitis B vaccine before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
This trial tests two different booster shots for meningitis B in young adults who already got the Bexsero vaccine at least 2.5 years ago. The goal is to see which booster works best to keep you protected.
This study tests a meningococcal B vaccine in adults who have had their spleen removed or have a spleen that doesn't work well (asplenia). It will compare how well the vaccine works in these patients versus healthy adults to see if it provides good protection.
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
This trial tests a new vaccine that helps protect against 6 types of meningococcal bacteria, which can cause serious infections like meningitis. It is for healthy people aged 2 to 59 years.
Hear when a new Transgender Persons trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.